Moors & Cabot, Inc. Exelixis, Inc. Transaction History

Moors & Cabot, Inc.

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 08, 2024	BUY	$20.17 - $23.93 $28,238 - $33,502	1,400 Added 15.05%	10,700 $253,000
Q4 2023 Feb 14, 2024	SELL	$19.25 - $24.13 $31,762 - $39,814	-1,650 Reduced 15.07%	9,300 $223,000
Q3 2023 Nov 07, 2023	SELL	$19.04 - $22.74 $2,856 - $3,410	-150 Reduced 1.35%	10,950 $239,000
Q2 2023 Aug 09, 2023	BUY	$18.17 - $20.48 $201,687 - $227,328	11,100 New	11,100 $212,000
Q3 2021 Nov 05, 2021	BUY	$16.3 - $21.14 $1.08 Million - $1.4 Million	66,340 New	66,340 $1.04 Million

460

240M

2.04M

1.29M

Ticker EXEL
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 321,832,000
Market Cap $8.46B
Description
Exelixis, Inc., an oncology-focused biotechnology company, focuses on the discovery, development, and commercialization of new medicines to treat cancers in the United States. The company's products include CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ ...

Get notified when there are updates to the investment portfolio of Moors & Cabot, Inc., based on Form 13F filings with the SEC.

Stay updated on Moors & Cabot, Inc. with notifications on news.